VPO · Digital health & life sciences
Virtual Privacy Officer for Biotech & Pharma Companies
A Virtual Privacy Officer gives a biotech or pharma company one accountable owner for the three-way split its data creates: key-coded trial records, patient support program enrolments held by a hub vendor, and the corporate and HCP data everyone else touches. The trigger is usually a live PSP whose hub vendor nobody has formally reviewed, a Quebec Law 25 question nobody can answer, or a breach notice that lands on a desk with no clear owner. Delivered from $2,200 CAD/month, a VPO keeps that accountability continuous instead of reconstructed after the fact.
Reviewed by the Privacy Horizon team · Last reviewed
What you're protecting
What a VPO owns across a biotech or pharma company's data
Privacy accountability in this sector cannot sit with one system or one team, because the three categories of sensitive data rarely share an owner.
The 'personal information' status of key-coded trial data
Whether coded trial records count as personal information in the sponsor's hands is a live analysis tied to re-identification risk, not a settled fact — and the VPO documents that answer rather than assuming it.
PSP accountability that outlives the hub contract
Enrolment, diagnosis and consent details processed inside a third-party hub still belong, legally, to a program the sponsor owns — accountability that has to be documented even when the sponsor never touches the raw data.
HCP and employee data across CRM and HR systems
Prescriber engagement records and internal employee files that fall under the same PIPEDA obligations as any other commercial personal information, but rarely get the same review attention as clinical systems.
Quebec Law 25 exposure for patient programs
PSPs and consumer-facing programs reaching Quebec residents carry provincial obligations layered on top of the federal baseline, which a VPO tracks separately from PIPEDA rather than assuming the two are identical.
Breach-reporting readiness that reaches beyond your own systems
A VPO prepares the company to report a breach that happened at a hub vendor or CRO just as readily as one that happened internally, since the sponsor's notification duty does not disappear because the incident occurred elsewhere.
Regulatory map
The privacy regime a biotech or pharma VPO keeps current
The rules that govern this data rarely stay still, and a part-time internal owner tends to fall behind exactly the questions a partner or regulator will ask first.
PIPEDA's real-risk breach standard
Federal law requires reporting to the OPC and affected individuals when a breach creates a real risk of significant harm, a threshold judgment a VPO makes with the facts of your specific PSP or trial incident in hand.
Coded-data identifiability under TCPS 2
Research ethics guidance treats coded information as identifiable when re-identification remains plausible, a distinction that directly shapes whether a given trial dataset needs the same protection as fully identified records.
Mandatory breach-record retention
PIPEDA requires organizations to keep records of every breach of safeguards, even ones not serious enough to report, for twenty-four months — records a VPO maintains as part of ongoing program hygiene.
Quebec's Law 25 for PSPs and consumer programs
Organizations processing Quebec residents' personal information face their own privacy impact and incident-notification expectations on top of PIPEDA, which a VPO reviews program by program rather than assuming blanket coverage.
What goes wrong
What VPO oversight is designed to catch in this environment
Most of the risk a VPO manages here is ownership risk — data nobody has formally claimed, sitting in a system nobody reviews.
A hub vendor breach with no assigned notifier
When a PSP hub is compromised, the question of whether the sponsor or the vendor notifies patients has to be answered in the contract before the incident, not argued about during it.
Trial data treated as anonymous when it isn't
Assuming key-coded data carries no privacy obligation because it looks de-identified is a common gap a VPO's classification review is built to close before a regulator or auditor finds it.
Marketing and CRM lists leaking outside sponsor control
HCP engagement and patient-program mailing lists held by third-party marketing platforms create exposure that still triggers the sponsor's own breach-reporting obligations under PIPEDA.
Quebec obligations missed on a national program
A patient support program built for a national rollout can miss Quebec-specific requirements entirely if nobody reviews enrolment by province, a gap that surfaces only when a complaint arrives.
Our vpo for biotech & pharma companies
What our VPO service covers for a biotech or pharma company
The same retainer structure our VPO service always delivers, applied specifically to trial-data classification, PSP hub oversight and Quebec readiness.
Privacy program leadership across three data types
A designated privacy coach who tracks trial, PSP and corporate data as three distinct accountability streams rather than one undifferentiated privacy program.
Monitoring and risk assessments tied to hub and CRO contracts
Regular review of the specific privacy risk each PSP hub, specialty pharmacy and CRO relationship carries, flagged before it becomes a diligence surprise.
Recurring audits ahead of licensing conversations
Documentation and reporting kept current enough that a partnering counterparty's diligence request does not trigger a scramble to reconstruct months of privacy activity.
Training calibrated to patient-services and lab teams
Awareness content that reflects how differently a patient-services rep handling diagnoses and a bench scientist handling unpublished data actually encounter privacy risk day to day.
Vendor and third-party compliance oversight
Ongoing guidance on what to demand of CROs, hubs and specialty pharmacies, and how to interpret the privacy commitments already sitting in existing agreements.
How the engagement runs
How a VPO retainer runs for a biotech or pharma company
Set up once, then maintained continuously rather than revisited only when something goes wrong.
Step 1
Map the data and the vendors
We identify every place trial, PSP and corporate data lives, and every CRO, hub or cloud vendor that touches it, before assigning ownership.
Step 2
Classify and document
Coded trial data is assessed for identifiability, PSP accountability is documented against the hub contract, and the resulting positions are written down, not left as institutional memory.
Step 3
Monitor on a recurring cadence
Monthly coaching and compliance monitoring keep the program current as vendors, systems and provincial exposure change.
Step 4
Respond and report when needed
When an incident occurs, the VPO runs the assessment and reporting decision under the real-risk standard, whether the incident originated internally or at a vendor.
What it costs
What a VPO retainer costs for a biotech or pharma company
Our Virtual Privacy Office starts from $2,200 CAD/month on a twelve-month term, billed monthly, and includes ten hours of monthly coaching, a designated privacy coach, an incident management protocol, and review of policies and vendor agreements, with training and human risk assessments for twenty-five seats.
For a biotech or pharma company, scope typically grows with the number of active PSP hub relationships, CRO contracts, and provinces the company's patient programs reach — a single-trial discovery company costs less to cover than a multinational affiliate running several PSPs across Canada. We confirm scope before quoting beyond the base retainer.
Biotech & Pharma Companies: VPO questions, answered
It depends on how plausible re-identification is, given what keys, codes and supplementary data the sponsor holds or could obtain. This is a documented judgment call, not a default assumption either way, and a VPO reviews it against your specific data architecture rather than applying a blanket rule to every trial.
Legally, accountability for the patient support program stays with the sponsor even when a third-party hub processes the identifiable data day to day. That means the sponsor's contract with the hub needs to specify notification duties and security expectations clearly, because 'the vendor holds it' does not transfer the sponsor's own obligations.
It adds Quebec-specific privacy impact assessment and incident-notification expectations for any program reaching Quebec residents, on top of PIPEDA's federal baseline. A VPO reviews each PSP and consumer program by province rather than assuming a Canada-wide rollout is automatically covered by one set of rules.
Both. Because so much of a biotech or pharma company's most sensitive data sits with third parties, VPO oversight explicitly covers CRO, hub and specialty-pharmacy relationships, not only systems the company operates directly.
A VPO answers questions of legal accountability and regulatory obligation — who owns notification duties, what Law 25 requires, whether trial data is personal information — while a vCISO answers questions of technical risk and architecture. The two roles work from the same facts but toward different deliverables.
More for biotech & pharma companies
Other services for this niche
About this service
What's Protecting Your Business from the Next Threat?
Don't wait for a breach to expose your vulnerabilities. Let Privacy Horizon secure your data, ensure compliance, and build lasting trust.